Matthew Ulrickson, MD, discusses a patient case of BPDCN, emphasizing the importance of recognizing and treating this rare disease, exploring various treatment options, and highlighting the evolving prognosis.
A 67-Year-Old Woman with R/R BPDCN
Expert insight into the diagnostic markers and challenges of BPDCN, including the importance of involving dermatologists and pathologists, to identify various disease presentations in both adult and pediatric patients.
Explores the intricate decision-making process for frontline treatment in BPDCN patients, with considerations for age, fitness, and various therapeutic approaches.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
